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Introduction 
In this supplementary appendix we present additional material to help interpret the findings presented in the main paper.  In part 
one, we define care homes and provide some international context. In part two, we present the characteristics of participants 
recruited after randomisation (Table S1). In part three we present data on depression in the care home population. In part four, we 
present information on analyses referred to, but not fully explained in the main paper: drug use, safety data, and the health 
economic analysis. 
 
Part one: Care homes: definition and international context 
The term care home in the context of the OPERA trial refers to UK residential and nursing homes. In the UK, care homes are 
typically small by international standards, with a typical median size of 30-40 places.
1
 Residential homes provide accommodation 
and personal care, while nursing homes also provide 24 hour nursing for those with multiple frailties or specific nursing needs. 
Internationally, care home size tends to be higher, with unit sizes of 100-150 typical, for example in the Netherlands 
2
 and in the 
U.S. 
3
 In all countries, concern about standards of care is found, 
4, 5
 while dementia prevalence is high in all care home settings. 
Demographic change means that care home use is sure to increase despite efforts to focus care in the community, 
6
 including from 
a very low base in developing countries.
7
  
 
 
Part Two: Characteristics of participants recruited after randomisation 
 
Table S1. End of study characteristics of participants recruited to study after randomisation included in end-of-study 
cross-sectional analyses.  
 Intervention  Control  
 % or 
mean 
Number 
or SD 
N % or 
mean 
Number 
or SD 
N 
N=127/132 providing usable outcome data at end of study  76   51 
Demographic data       
 Female 78% 59 76 80% 41 51 
 White  97% 74 76 98% 50 51 
 Taking  antidepressants  24% 18 76 29% 14 49 
 Age (at recruitment) 87·9 8·0 76 87·9 7·2 51 
 Age left full-time education 14.7 2·0 63 15·4 2.0 39 
Assessment data   76   49 
 Depressed (GDS-15 ≥5 or equivalent) a 46% 27 59 54% 23 43 
 GDS-15 score (0-15, 0 =best) 5·0 3·8 59 5·2 3·5 43 
 MMSE score (0-30, 30 =best) 20·4 6·4 55 16·8 6·6 41 
 SPPB score (0-12, 12 =best) 1·8 2·3 61 1·5 2·1 44 
 EQ-5D score (-0.594 to 1, 1 =best) 0·53 0·35 53 0·55 0·40 33 
 Pain today   56   40 
  None 71% 40  82% 33  
  Mild-Moderate 29% 16  15% 6  
  Severe 0% 0  3% 1  
 Fear of falling 44% 25 57 30% 12 40 
Proxy data   76   51 
 Social engagement    75   48 
 High 20% 15  6% 3  
 Medium 21% 16  29% 14  
 Low 59% 45  65% 31  
 Barthel Index (0-100, 100 =best) 61.6 26·6 66 57·3 28·8 42 
 Proxy EQ-5D (-0.594 to 1, 1 =best) 0·51 0·38 75 0·44 0·37 50 
Comorbidities recorded in home records       
 Cancer  4% 3 76 10% 5 50 
 Stroke 20% 15 76 26% 13 50 
 Dementia 11% 8 76 33% 17 51 
 Depression 12% 9 76 16% 8 50 
 Anxiety 16% 12 76 16% 8 50 
 Osteoporosis 15% 11 76 10% 5 50 
 Chronic lung disease 14% 11 76 6% 3 50 
 Urinary incontinence 40% 30 75 67% 34 51 
a If fewer than 15 items on the Geriatric Depression Scale were completed then we considered ‘depression’ present; if five positive responses, 13 or more 
items are completed, four when 12 or 11 items are completed and three when 10 items are completed.  Nine or fewer items completed was considered 
missing. 
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Part Three: Depression 
Data reveal that of the 891 residents recruited to the cohort study 374 (42%) were classified as depressed at baseline assessment 
(GDS-15) (Main paper, Table 2). Data from the care homes reveals that in home records only 180/878 (20·5%) had a recognisable 
diagnosis of depression (Main paper, Table 2) and of the depressed cohort only 92/365 (25%) had a depression diagnosis recorded 
(Table S2).   
 
These data suggest that depression is a considerable problem in the elderly care home population and further exploration of the 
diagnosis and appropriate treatments is still needed. 
 
Table S2 Co-morbidities in depressed cohort participants 
N=374 Group 
 Intervention n=174 Control n=200 
 N (%) N (%) 
Cancer   7/ 169 4  20/ 195 10 
Stroke  43/ 169 25   50/ 197 25 
Dementia  37/ 169 22   42/ 197 21 
Depression  45/ 169 27  47/ 196 24 
Anxiety  34/ 169 20  39/ 195 20 
Osteoporosis  14/ 169 8  18/ 195 9 
Chronic lung disease  22/ 168 13  19/ 197 10 
Urinary incontinence   99/ 169 59  111/ 197 56 
Three individuals in this cohort did not consent to have data collected from their records 
 
 
Part Four: Drug use, mental health team visits, safety data, economic analysis 
Antidepressant use 
We collected data on all medications used over a one week period from the home records prior to randomisation, then repeated at 
three, six, nine and 12 month after randomisation. We extracted the exact drug name (as written in care home records), 
preparation, and dose used plus the number of times any medication was actually administered over a one week period. We then 
used the prescription cost analysis database to attach a code to each unique preparation used. 
8
 Using this methodology we 
calculated and estimated total amount used of each individual drug listed in the British National Formulary. 
9
 We included drugs 
in British National Formulary sections 4.3.1 Tricyclic and related antidepressant drugs, 4.3.3 Selective serotonin re-uptake 
inhibitors and 4.3.4 other antidepressant drugs in this analysis. Number of defined daily doses (DDDs) of antidepressants used 
was derived from the total mg of each antidepressant medication given in seven days from medical records data.  These data were 
converted into defined daily doses using standard criteria (http://www.whocc.no/atc_ddd_index/).  We excluded data on 
participants prescribed with low-dose (≤25 mg /day) amitriptyline which is typically used in pain management.  We then 
interpolated forwards and backwards, in multiples of seven, to the midpoint date between each data collection visit to the homes.  
For residents who died, the interpolation value was scaled by the proportion of the time interval survived if this was less than a 
half.  Otherwise a half was used, as was the case for residents who moved away from participating homes.  For residents not 
taking any antidepressants in a time interval, their number of defined daily doses was set to zero for that interval. We used a linear 
mixed model
 
to compare proportions taking antidepressant medication, a Mann-Whitney U test to compare number of defined 
daily doses of medication used and a mixed effects logistic regression to test for any differences in changes in who received 
antidepressant between baseline and one year. We did not find any significant differences in medication use (Table S3). 
 
Table S3. Antidepressant use by those in cohort analysis during study  
 Intervention Control 
 % or 
mean and 
median 
number or 
SD, 90
th
 
centile 
N % or 
mean and 
median 
number or 
SD, 90
th
 
centile 
N 
Drugs Cohort Baseline (N = 869)   392   477 
Antidepressant use in previous week a       
Baseline 28% 110 392 31% 150 477 
3 months 28% 100 359 31% 131 427 
6 months 29% 97 335 31% 124 395 
9 months 29% 88 306 29% 105 364 
12 months 29% 83 284 31% 103 333 
Defined daily doses of medication over all follow-up b       
 59 123, 242 392 76 171, 282 477 
Changes in antidepressant prescribing in those present at 
randomisation and end of follow-up c 
  282   333 
At baseline and at 12m 26% 73  25% 84  
Only at 12m 4% 10  6% 19  
Only at baseline 4% 10  3% 11  
Never on drug 67% 189  66% 219  
a P-value from linear mixed model is 0·7779, b P-value from Mann-Whitney U test is 0·1677, c P-value from mixed effects logistic model is 0·2263 
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Mental health team visits 
We collected data on visits by health professionals, including visits from the community mental health team, three, six, nine, and 
12 months after randomisation from care home records. There were 168 such visits to 70 participants (range 1-17).  In the control 
group 34/493 (7%) and in the intervention group 36/398 (9%) had one or more visit from the mental health team. We did not 
collect data on the reasons for these visits or whether the mental health team contact started before or after randomisation. These 
data do not suggest that our control intervention led to an increase in non-pharmacological treatments for depression. 
 
Safety data 
Everyone living in the intervention homes was exposed to the exercise intervention, including those who were not study 
participants. Safety monitoring, therefore, included all residents. We monitored any directly attributable adverse events that 
occurred during the exercise groups or during study assessments. We defined a directly attributable adverse event as an event that 
required external medical attention as consequence of participation in in the study. 
 
To obtain an overall picture for each home during the intervention period we used the routinely collected data that care homes are 
required to keep on deaths and fractures. Care homes are specifically required to record and report deaths and serious injury, 
including falls and fractures under Regulation 37, Part V11 of The Care Home Regulations (2001). 10 We extracted pooled 
anonymous data unlinked to identity for the preceding three months from each home for all residents (participants and non-
participants) three, six, nine and 12 months after randomisation. 
 
At the end of the study Hospital Episodes Statistics Secondary Uses Service data were collected from each Primary Care Trust in 
which the study had been run. 11 The data included data for accident and emergency department attendances, hospital admissions, 
and outpatient attendances, with a diagnostic code. 
 
Fractures of interest were pre-specified as peripheral fractures, defined as fractures not involving the spine. All spinal fractures 
were excluded as these are not strongly related to falls injury. We identified all fracture codes in The International Statistical 
Classification of Diseases and Related Health Problems tenth revision (ICD-10) 
12
 and then searched diagnostic descriptions from 
the inpatient, outpatient and accident and emergency departments for fracture diagnoses. 
 
One fracture event may lead to multiple health service encounters, for example an accident and emergency department attendance, 
followed by an admission and a subsequent outpatient appointment. We, therefore, cross referred between datasets to identify 
linked episodes that represented a single fracture event. The quality of coding in accident and emergency data was poor; typically 
these reported an attendance accompanied by a broad, non-specific diagnostic description of ‘dislocation/fracture/joint 
injury/amputation’. Out-patient data typically reported clinic attended but not the diagnosis. We were not able to link these to care 
home records data on fractures as these had been provided to us as pooled anonymous data. Where a participant had multiple 
peripheral fractures for one episode of care, this was treated as a single fracture event. We then allocated events to different levels 
of certainty that there had been a fracture: 
 
 Confirmed fracture; definite fracture code identified, typically an inpatient admission. 
 Probable fracture; an A&E attendance followed by an orthopaedic outpatient appointment. 
 Potential fracture; an A&E attendance for an injury in which the term fracture appeared (amongst other diagnostic 
terms) in the diagnostic description with no further data provided. 
 
During the study we used death data collected from homes to monitor safety.  For the final end-of study analysis we used the more 
robust routine health service data. At the end of the study we collected data on date for whom we had permission to access their 
medical record data, from the National Health Service’s Medical Record Information Service. 13  
 
Two of our safety analyses (on fracture and death rates) were based on data relating to study participants and conducted in a 
similar fashion to our primary and secondary analyses, using mixed effects logistic models. The third analysis was of fractures 
amongst all care home residents (aggregated fracture level). These fractures could not be attributed to individuals so we used a 
Poisson model at the care home level, adjusting for clustering with a random effect, and home location, home size, home type, 
mean age of home participants at pre-randomisation baseline, proportion female, percentage on antidepressants at pre-
randomisation baseline, proportion of residents with moderate or severe cognitive impairment at pre-randomisation baseline 
assessment. 
 
There were no directly attributable adverse events.  There were no differences in deaths and fractures between the intervention and 
control homes (Table S4) 
 
5 
 
 
 
 
Table S4. Peripheral fractures and deaths 
Outcome Denominators Intervention Control Effect estimate 95% CI ICC p 
Number of  peripheral fractures        
       Care home data (all residents=2133) 973, 1160 48 42 IRR=1·14
 a (0·80 to 1·63) 0·03 0·5581 
       NHS data (all participants) 501, 553 33 39 Risk difference = -0·005   0·7648
 b 
         Definite (fracture code identified, typically inpatient)  27 28     
         Probable (A&E and outpatient appointment)   1 7     
         Possible (A&E ‘fracture’ in diagnostic description)   5 4     
All cause mortality        
    Participants present  after randomisation 501, 553 119 122 OR=1·07 
c (0·78 to 1·48) 0·02 0·6745 
    Participants present at randomisation 402, 499   OR=1·08
 c (0·79 to 1·50) 0·001 0·6173 
aMixed effects Poisson model at the care home level, adjusting for mean age of residents, proportion of females, proportion of residents on antidepressants, proportion of residents with moderate to severe cognitive impairment, 
size of home, site, type of home and clustering with a random effect, IRR is incidence rate ratio.  bχ2 test. cOdds Ratio, derived from mixed effects logistic model, adjusting for mean age of residents, proportion of females, 
proportion of residents on antidepressants, proportion of residents with moderate to severe cognitive impairment, size of home, site and type of home.  
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Health economic analysis 
Data for the economic evaluation covered a 12 month time period from when the home was randomised.  A priori we chose to use 
proxy EQ-5D for this analysis as a poor rate of self-completion was anticipated. To ensure that quality adjusted life year (QALY) 
calculations were as accurate as possible we used multiple imputation to guard against any bias that may result from missing 
proxy EQ-5D scores. Since the study was cluster randomised rather than individual randomised, the data were multilevel. To 
adjust for this characteristic of the data, a multiple imputation model that accounted for clustering (by means of a random cluster 
effect) by care home was used to generate the missing proxy EQ-5D scores at each of the five time points (baseline and three, six, 
nine, and 12 months). The imputation model used the auxiliary variables home size, baseline age of resident and proxy EQ-5D 
scores at all five time points. We calculated the total utility for each participant from point estimates at baseline, three, six, nine 
and 12 months, using the ‘area under the curve’. We assumed the utility for each person followed a linear trend line between these 
point estimates, 
14
 including those who died over the course of the study.  
 
We collected data needed to calculate costs at the individual-level from routine Primary Care Trust data provided after the study 
was finished and through the care home records at three, six, nine, and 12 months.  For resource use coming from care home 
records and community data provided by Primary Care Trusts, we obtained unit costs for the UK from published sources. 
8, 15
 Unit 
costs for medications were obtained from the Prescription Cost Analysis database for 2010, 
8
 and unit costs for hospital visits were 
obtained from the Primary Care Trust data.  As the outpatient data had a large proportion of missing costs, and these missing data 
were more frequent with some Primary Care Trusts than with others, we imputed these data using the same methodology as we 
did for the missing EQ-5D scores before calculating the total outpatient cost. We estimated the cost of intervention from study 
data. 
 
Because non-study participants were also exposed to the intervention and a proportion of the cost could also be attributable to 
them we used a weighted cost per resident. The fixed cost of providing the exercise classes was divided by the overall percentage 
of residents assessed as eligible to participate in the exercise sessions. This method reflected the whole home aspect of the 
intervention while removing the cost burden from those residents who were unlikely to receive much benefit from the programme 
due to communication difficulties or serious illness. 
 
Our primary analysis was a cost-utility analysis over 12 months examining the cost per QALY gained for all participants who 
were assessed for proxy EQ-5D prior to randomisation and had Primary Care Trust data extracts. The clustering by home and the 
correlation between individual costs and outcomes needed to be considered in the cost-effectiveness analysis, so we used bivariate 
normal mixed models with cluster random effects. 
16
 We used multilevel multiple imputation of EQ-5D and outpatient data to 
handle the missing data, creating  five imputed data sets of total costs and  EQ-5D scores from which we calculated total costs and 
total QALYs. 
17
 Estimates of incremental costs and incremental QALYs obtained from each imputed set were combined using 
Rubin’s rules to obtain multiple imputation estimates and standard errors. 18 
 
We plotted the cost-effectiveness plane, but calculated a mean incremental cost-effectiveness ratio only if it would be informative. 
For example, with data that show an insignificant quality-adjusted life year gain, it was more informative to report disaggregated 
data on costs and effects than report a mean incremental cost-effectiveness ratio. Since a definite threshold has proven difficult to 
set empirically, we planned to assess the cost-utility of the intervention using willingness to pay thresholds ranging between £0 
and £40,000. 
19
  We did two sensitivity analyses; excluding high cost individuals (top 5%) and including costs from the societal 
perspective. 
 
The base case analysis found the incremental QALY figure to favour the control arm of the study, the difference was negligible 
(0·0014) with a wide confidence interval (-0·073 to 0·070) (Table S5). The wide confidence interval means that we cannot 
formally conclude equivalence in QALYs since the limits of the 95% confidence interval include values where we might have 
concluded that the intervention was cost effective. In the cost-effectiveness plane the majority of results are in the north east 
quadrant (Figure S1).  The sensitivity analyses gave similar results (Table S5) 
 
The cost utility analysis shows that the intervention is dominated by the control demonstrating fairly conclusively that this is not a 
cost-effective intervention.    
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Table S5. Mean differences from the bivariate mixed models for the baseline and sensitivity analyses.  
Measure  Mean difference 
(intervention – control) 
95% CI 
Base case analysis Total costs £ 374 -655 to 1404 
 QALY -0·001 -0·073 to 0·070 
Excluding high cost participants Total costs £ 402 -224 to 1028 
 QALY -0·002 -0·076 to 0·072 
Societal perspective Total costs £ 366 -664 to 1396 
 QALY -0·001 -0·073 to 0·070 
 
 
 
 
 
Figure S 1. Cost-effectiveness plane generated from bootstrapped mean cost and QALY differences for residents over 12 
months.  
 
 
 
Positive values indicate that the intervention was more costly or more effective. 
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CONSORT Statement 
Table S6 CONSORT 2010 checklist of information to include when reporting a cluster randomised trial  
Section/Topic Item 
No 
Standard Checklist item Extension for cluster 
designs 
Section 
of 
paper 
Title and abstract  
 1a Identification as a randomised 
trial in the title 
Identification as a cluster randomised 
trial in the title 
Title 
1b Structured summary of trial 
design, methods, results, and 
conclusions (for specific guidance 
see CONSORT for abstracts)i,ii 
See table 2 Abstract 
Introduction  
Background and 
objectives 
2a Scientific background and 
explanation of rationale 
Rationale for using a cluster design Background 
2b Specific objectives or hypotheses Whether objectives pertain to the 
cluster level, the individual participant 
level or both 
Methods 
Methods  
Trial design 3a Description of trial design (such as 
parallel, factorial) including 
allocation ratio 
Definition of cluster and description of 
how the design features apply to the 
clusters 
Methods 
3b Important changes to methods 
after trial commencement (such 
as eligibility criteria), with reasons 
 N/A 
Participants 4a Eligibility criteria for participants Eligibility criteria for clusters  Methods 
4b Settings and locations where the 
data were collected 
 Methods & Results 
Interventions 5 The interventions for each group 
with sufficient details to allow 
replication, including how and 
when they were actually 
administered 
Whether interventions pertain to the 
cluster level, the individual participant 
level or both 
Complex 
intervention only 
summarised 
Outcomes 6a Completely defined pre-specified 
primary and secondary outcome 
measures, including how and 
when they were assessed 
Whether outcome measures pertain to 
the  cluster level, the individual 
participant level or both 
Methods 
6b Any changes to trial outcomes 
after the trial commenced, with 
reasons 
 N/A 
Sample size 7a How sample size was determined Method of calculation, number of 
clusters(s) (and whether equal or 
unequal cluster sizes are assumed), 
cluster size, a coefficient of intracluster 
correlation (ICC or k), and an indication 
of its uncertainty 
Methods (sample 
size) 
7b When applicable, explanation of 
any interim analyses and stopping 
guidelines 
 N/A 
Randomisation:  
 Sequence generation 8a Method used to generate the 
random allocation sequence 
 Methods 
(recruitment and 
randomisation) 
8b Type of randomisation; details of 
any restriction (such as blocking 
and block size) 
Details of stratification or matching if 
used 
as above 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement 
the random allocation sequence 
(such as sequentially numbered 
containers), describing any steps 
Specification that allocation was based 
on clusters rather than individuals and 
whether allocation concealment (if any) 
was at the cluster level, the individual 
as above 
9 
 
taken to conceal the sequence 
until interventions were assigned 
participant level or both 
 Implementation 
 
10 Who generated the random 
allocation sequence, who enrolled 
participants, and who assigned 
participants to interventions 
Replace by 10a, 10b and 10c as above 
 10a  Who generated the random allocation 
sequence, who enrolled clusters, and 
who assigned clusters to interventions 
 
Methods 
 10b  Mechanism by which individual 
participants were included in clusters 
for the purposes of the trial (such as 
complete enumeration, random 
sampling) 
Methods 
(randomisation and 
recruitment) 
 10c  From whom consent was sought 
(representatives of the cluster, or 
individual cluster members, or both), 
and whether consent was sought before 
or after randomisation 
 
As above 
     
Blinding 11a If done, who was blinded after 
assignment to interventions (for 
example, participants, care 
providers, those assessing 
outcomes) and how 
 Methods (Masking) 
11b If relevant, description of the 
similarity of interventions 
 Methods 
(Interventions) 
Statistical methods 12a Statistical methods used to 
compare groups for primary and 
secondary outcomes 
How clustering was taken into account Methods (Analysis) 
12b Methods for additional analyses, 
such as subgroup analyses and 
adjusted analyses 
 N/A 
Results  
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of 
participants who were randomly 
assigned, received intended 
treatment, and were analysed for 
the primary outcome 
For each group, the numbers of clusters 
that were randomly assigned, received 
intended treatment, and were analysed 
for the primary outcome 
Results (Consort 
figures) 
13b For each group, losses and 
exclusions after randomisation, 
together with reasons 
For each group, losses and exclusions 
for both clusters and individual cluster 
members 
Results 
Recruitment 14a Dates defining the periods of 
recruitment and follow-up 
 Results 
14b Why the trial ended or was 
stopped 
 N/A 
Baseline data 15 A table showing baseline 
demographic and clinical 
characteristics for each group 
Baseline characteristics for the 
individual and cluster levels as 
applicable for each group 
Results (tables) 
Numbers analysed 16 For each group, number of 
participants (denominator) 
included in each analysis and 
whether the analysis was by 
original assigned groups 
For each group, number of clusters 
included in each analysis 
Results (Tables, 
consorts and text) 
Outcomes and 
estimation 
17a For each primary and secondary 
outcome, results for each group, 
and the estimated effect size and 
its precision (such as 95% 
confidence interval) 
Results at the individual or cluster level 
as applicable and a coefficient of 
intracluster correlation (ICC or k) for 
each primary outcome 
Results (Tables, 
and text) 
17b For binary outcomes,  N/A 
10 
 
presentation of both absolute and 
relative effect sizes is 
recommended 
Ancillary analyses 18 Results of any other analyses 
performed, including subgroup 
analyses and adjusted analyses, 
distinguishing pre-specified from 
exploratory 
 N/A 
Harms 19 All important harms or 
unintended effects in each group 
(for specific guidance see 
CONSORT for harmsiii) 
 N/A 
Discussion  
Limitations 20 Trial limitations, addressing 
sources of potential bias, 
imprecision, and, if relevant, 
multiplicity of analyses 
 Discussion 
Generalisability 21 Generalisability (external validity, 
applicability) of the trial findings 
Generalisability to clusters and/or 
individual participants (as relevant) 
Discussion and 
research in context 
Interpretation 22 Interpretation consistent with 
results, balancing benefits and 
harms, and considering other 
relevant evidence 
 Discussion 
Other information   
Registration 23 Registration number and name of 
trial registry 
 Title page 
Protocol 24 Where the full trial protocol can 
be accessed, if available 
 References 
Funding 25 Sources of funding and other 
support (such as supply of drugs), 
role of funders 
 Acknowledgements 
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